Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?

被引：4
作者：
Markman, Maurie [1 ,2 ]
机构：
[1] Canc Treatment Ctr Amer, Philadelphia, PA USA
[2] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA
来源：
ONCOLOGIST | 2016年 / 21卷 / 05期
关键词：
GYNECOLOGIC-ONCOLOGY-GROUP; PERITONEAL CARCINOMATOSIS; PROGNOSTIC-FACTORS; PRIMARY SURGERY; TRIAL;
D O I：
10.1634/theoncologist.2015-0486
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：529 / 531
页数：3
相关论文
共 13 条
[1]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[2]   Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer - A systematic review with melaanalyses [J].
Elit, Laurie ;
Oliver, Thomas K. ;
Covens, Allan ;
Kwon, Janice ;
Fung, Michael -Kee Fung ;
Hirte, Holger W. ;
Oza, Amit M. .
CANCER, 2007, 109 (04) :692-702
[3]   A contemporary analysis of morbidity and outcomes in cytoreduction/ hyperthermic intraperitoneal chemoperfusion [J].
Haslinger, Michelle ;
Francescutti, Valerie ;
Attwood, Kristopher ;
McCart, Judith Andrea ;
Fakih, Marwan ;
Kane, John M., III ;
Skitzki, Joseph J. .
CANCER MEDICINE, 2013, 2 (03) :334-342
[4]   The Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer [J].
Helm, C. William .
ONCOLOGIST, 2009, 14 (07) :683-694
[5]   Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial [J].
Kehoe, Sean ;
Hook, Jane ;
Nankivell, Matthew ;
Jayson, Gordon C. ;
Kitchener, Henry ;
Lopes, Tito ;
Luesley, David ;
Perren, Timothy ;
Bannoo, Selina ;
Mascarenhas, Monica ;
Dobbs, Stephen ;
Essapen, Sharadah ;
Twigg, Jeremy ;
Herod, Jonathan ;
McCluggage, Glenn ;
Parmar, Mahesh ;
Swart, Ann-Marie .
LANCET, 2015, 386 (9990) :249-257
[6]   Looking up: Recent advances in understanding and treating peritoneal carcinomatosis [J].
Lambert, Laura A. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2015, 65 (04) :283-298
[7]   Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study [J].
Landrum, Lisa M. ;
Java, James ;
Mathews, Cara A. ;
Lanneau, Grainger S., Jr. ;
Copeland, Larry J. ;
Armstrong, Deborah K. ;
Walker, Joan L. .
GYNECOLOGIC ONCOLOGY, 2013, 130 (01) :12-18
[8]  
National Cancer Institute, NCL CLIN ANN INTR CH
[9]   Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study [J].
Tewari, Devansu ;
Java, James J. ;
Salani, Ritu ;
Armstrong, Deborah K. ;
Markman, Maurie ;
Herzog, Thomas ;
Monk, Bradley J. ;
Chan, John K. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) :1460-1466
[10]   Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer [J].
Vergote, Ignace ;
Trope, Claes G. ;
Amant, Frederic ;
Kristensen, Gunnar B. ;
Ehlen, Tom ;
Johnson, Nick ;
Verheijen, Rene H. M. ;
van der Burg, Maria E. L. ;
Lacave, Angel J. ;
Panici, Pierluigi Benedetti ;
Kenter, Gemma G. ;
Casado, Antonio ;
Mendiola, Cesar ;
Coens, Corneel ;
Verleye, Leen ;
Stuart, Gavin C. E. ;
Pecorelli, Sergio ;
Reed, Nick S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (10) :943-953
12